Kathryn Russell

Kathryn Russell

Auto-generated profile, based on publicly available information

Kathryn Russell

Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2024 in Blood Advances
Verified
Journal Article
Open access
KPKhushboo V. Pal
Khushboo V. Pal
MOMegan Othus
Megan Othus
ZAZahra Ali
Zahra Ali
KRKatherine Russell
Katherine Russell
CSCarole Shaw
Carole Shaw
AHAnna B. Halpern
Anna B. Halpern
Febrile neutropenia (FN) is the most common reason for hospital readmission after chemotherapy for acute myeloid leukemia (AML) and is a major driver of health care resource utilization. Although FN risk models exist, they have largely been developed and validated for solid tumors. We therefore examined whether baseline characteristics could predict which patients with AML and FN have a lower risk of progression to severe illness. We identified adults with high-grade myeloid neoplasms (≥10% blasts in the blood/marrow) who received intensive chemotherapy and who were admitted for FN between 2016 and 2023. We collected baseline clinical and disease variables. Outcomes were: infections identified, hospital length of stay (LOS), intensive care unit (ICU) admission, and survival. A lower-risk (LR) outcome was defined as LOS <72 hours without ICU admission or inpatient death. Univariate and multivariable (MV) logistic regression models were used to assess covariate associations with outcomes. We identified 397 FN admissions in 248 patients (median age, 61; [range, 29-77] years). The median hospital LOS was 6 days (range, 1-56) days; 10% required ICU admission, and 3.5% died inpatient. Only 15% of admissions were LR. Infection was identified in 59% of admissions. Physiologic parameters, including heart rate, blood pressure, and fever height, were the best predictors of LR admission and infection. We developed MV models to predict LR admission and infection with area under the curve (AUC) of 0.82 and 0.72, respectively. Established FN and critical illness models were not predictive of outcomes in AML, and we could not identify a LR group; thus, an AML-specific FN risk model requires further development and validation.

12 May 2025 in Blood Neoplasia
Verified
Journal Article
Open access
BDBrandon DaSilva
Brandon DaSilva
ADAlicia Darwin
Alicia Darwin
AZAmy Zhang
Amy Zhang
RVRutu D. Vyas
Rutu D. Vyas
KRKathryn Russell
Kathryn Russell
MLMarlise R. Luskin
Marlise R. Luskin
• Real-world efficacy and safety of the C10403 regimen in AYA patients with newly diagnosed ALL match prospective trial results. • Completing the regimen through maintenance therapy remains a challenge for patients and clinicians in adult oncology clinics.

24 June 2026 in Blood Advances
Verified
Journal Article
Open access
CLCatherine Thuy Khanh Le
Catherine Thuy Khanh Le
AZAmy Zhang
Amy Zhang
RVRutu D Vyas
Rutu D Vyas
JOJoanne Otani
Joanne Otani
KRKathryn Russell
Kathryn Russell
ELEmily C. Liang
Emily C. Liang
Relapse in the central nervous system (CNS) is a devastating outcome in acute lymphoblastic leukemia (ALL). Allogeneic hematopoietic cell transplantation (HCT) in ALL is reserved for patients with high-risk and/or relapsed/refractory disease. However, there is a paucity of data describing the incidence and factors associated with post-HCT CNS relapse in the modern era. In this multicenter retrospective study of adults with ALL who underwent first HCT between 2011 and 2021 at Stanford Health Care (SHC) or University of Washington/Fred Hutch Cancer Center (UW/FH), we aimed to describe the incidence of post-HCT CNS relapse, factors associated with post-HCT CNS relapse, and the impact of CNS relapse on overall survival (OS). A total of 636 patients were included. The 1- and 3-year cumulative incidences of CNS relapse after HCT were 3% and 6%, respectively. Absence of CNS involvement prior to HCT, pre-HCT MRD negativity, and receipt of TBI-based conditioning were significantly associated with decreased risk of post-HCT CNS relapse. These three characteristics defined a composite low-risk group that was associated with lower risk of post-HCT relapse [HR = 0.31 (95% CI, 0.15-0.68), p = 0.0032]. Post-HCT CNS relapse was significantly associated with shorter overall survival [HR 7.33 (95% CI, 5.12-10.49), p < 0.0001]; worse outcomes were seen with earlier post-HCT CNS relapse. Future studies will be needed to assess if this low-risk group may benefit from de-escalation of CNS-directed interventions during HCT.

1 November 2025 in JCO Oncology Practice
Verified
Journal Article
Closed access
MWMatthew Wu
Matthew Wu
KRKathryn Russell
Kathryn Russell
CSCarole M. Shaw
Carole M. Shaw
AHAnna B. Halpern
Anna B. Halpern
CGCristina Ghiuzeli
Cristina Ghiuzeli
MPMary-Elizabeth M. Percival
Mary-Elizabeth M. Percival
PURPOSE: Heart failure is a leading cause of death in patients with AML, who face higher risks of cardiac complications than nonleukemic cancer patients treated with anthracyclines. This study examines factors associated with myocardial dysfunction and recovery occurring during treatment of AML. METHODS: We retrospectively analyzed patients with AML who sustained reduced left ventricular ejection fraction (LVEF) during induction therapy at the University of Washington/Fred Hutchinson Cancer Center (2008-2022). Multivariable analysis compared characteristics between patients who eventually recovered LVEF and those who did not, with survival analysis performed by landmark censoring. RESULTS: Of 86 patients with AML diagnosed with systolic dysfunction, 41 (48%) failed to recover LVEF. These patients were more frequently male, older than 60 years, had preexisting cardiovascular risk factors, and leukemias of higher risk. Ischemia-related systolic failure was associated with nonrecovery (B = –2.89, P = .005), whereas chemotherapy-related dysfunction was associated with eventual recovery (B = 1.15, P = .014). Frequent use and higher doses of guideline-directed medical therapy (GDMT) were found among patients who recovered LVEF. Failure to recover cardiac function was associated with a greater incidence of cardiac-specific mortality (51% v 23%, P = .042), although impact on overall survival was unclear. CONCLUSION: Our retrospective single-center analysis suggests that approximately half of the patients with AML who experience LVEF decline during induction will not recover. Ischemic events during treatment were predictive of nonrecovery. The use of GDMT may improve prognosis for some patients. Given the impact of recovery, we propose the prospective verification and establishment of cardiac management algorithms in patients with AML.